Literature DB >> 11711428

Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas.

K Inoue1, F Zindy, D H Randle, J E Rehg, C J Sherr.   

Abstract

Loss of Dmp1, an Arf transcriptional activator, leads to spontaneous tumorigenesis in mice, causing death from various forms of cancer by two years of age. Retention and expression of the wild-type Dmp1 allele in tumors arising in Dmp1(+/-) mice demonstrate that Dmp1 can be haplo-insufficient for tumor suppression. The mean latency of E(mu)-Myc-induced B-cell lymphomas is halved on a Dmp1(-/-) or Dmp1(+/-) genetic background. Although p53 mutations or Arf deletion normally occur in approximately 50% of E(mu)-Myc-induced lymphomas, Dmp1 loss obviates selection for such mutations, indicating that Dmp1 is a potent genetic modifier of the Arf-p53 pathway in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11711428      PMCID: PMC312824          DOI: 10.1101/gad.929901

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  38 in total

Review 1.  Mdm2: the ups and downs.

Authors:  T Juven-Gershon; M Oren
Journal:  Mol Med       Date:  1999-02       Impact factor: 6.354

Review 2.  Signaling to p53: breaking the MDM2-p53 circuit.

Authors:  C Prives
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

3.  Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.

Authors:  C M Eischen; J D Weber; M F Roussel; C J Sherr; J L Cleveland
Journal:  Genes Dev       Date:  1999-10-15       Impact factor: 11.361

4.  Cloning and chromosomal localization of the gene encoding human cyclin D-binding Myb-like protein (hDMP1).

Authors:  S M Bodner; C W Naeve; K M Rakestraw; B G Jones; V A Valentine; M B Valentine; F W Luthardt; C L Willman; S C Raimondi; J R Downing; M F Roussel; C J Sherr; A T Look
Journal:  Gene       Date:  1999-03-18       Impact factor: 3.688

5.  Cdkn2a encodes functional variation of p16INK4a but not p19ARF, which confers selection in mouse lung tumorigenesis.

Authors:  C R Herzog; S Noh; L E Lantry; K L Guan; M You
Journal:  Mol Carcinog       Date:  1999-06       Impact factor: 4.784

6.  Tumor spectrum in ARF-deficient mice.

Authors:  T Kamijo; S Bodner; E van de Kamp; D H Randle; C J Sherr
Journal:  Cancer Res       Date:  1999-05-01       Impact factor: 12.701

Review 7.  The INK4A/ARF locus and its two gene products.

Authors:  N E Sharpless; R A DePinho
Journal:  Curr Opin Genet Dev       Date:  1999-02       Impact factor: 5.578

8.  Twist is a potential oncogene that inhibits apoptosis.

Authors:  R Maestro; A P Dei Tos; Y Hamamori; S Krasnokutsky; V Sartorelli; L Kedes; C Doglioni; D H Beach; G J Hannon
Journal:  Genes Dev       Date:  1999-09-01       Impact factor: 11.361

9.  A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice.

Authors:  E C Holland; W P Hively; R A DePinho; H E Varmus
Journal:  Genes Dev       Date:  1998-12-01       Impact factor: 11.361

10.  Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1.

Authors:  K Inoue; M F Roussel; C J Sherr
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

View more
  55 in total

Review 1.  Comparative pathogenesis of epsilonretroviruses.

Authors:  Donald Holzschu; Lorie A Lapierre; Michael D Lairmore
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

2.  Reduction of Pten dose leads to neoplastic development in multiple organs of Pten (shRNA) mice.

Authors:  Hong Shen-Li; Susan Koujak; Matthias Szablocs; Ramon Parsons
Journal:  Cancer Biol Ther       Date:  2010-12-01       Impact factor: 4.742

3.  Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Cancer Invest       Date:  2018-11-05       Impact factor: 2.176

4.  Hypergrowth mTORC1 signals translationally activate the ARF tumor suppressor checkpoint.

Authors:  Alexander P Miceli; Anthony J Saporita; Jason D Weber
Journal:  Mol Cell Biol       Date:  2011-11-07       Impact factor: 4.272

5.  Expression of Dmp1 in specific differentiated, nonproliferating cells and its regulation by E2Fs.

Authors:  A Mallakin; P Taneja; L A Matise; M C Willingham; K Inoue
Journal:  Oncogene       Date:  2006-07-31       Impact factor: 9.867

6.  Stabilization of the p53-DNA Complex by the Nuclear Protein Dmp1α.

Authors:  Robert D Kendig; Fumitake Kai; Elizabeth A Fry; Kazushi Inoue
Journal:  Cancer Invest       Date:  2017-04-13       Impact factor: 2.176

Review 7.  HIC1 (Hypermethylated in Cancer 1) epigenetic silencing in tumors.

Authors:  Capucine Fleuriel; Majid Touka; Gaylor Boulay; Cateline Guérardel; Brian R Rood; Dominique Leprince
Journal:  Int J Biochem Cell Biol       Date:  2008-08-03       Impact factor: 5.085

Review 8.  Role of DMP1 and its future in lung cancer diagnostics.

Authors:  Takayuki Sugiyama; Donna P Frazier; Pankaj Taneja; Rachel L Morgan; Mark C Willingham; Kazushi Inoue
Journal:  Expert Rev Mol Diagn       Date:  2008-07       Impact factor: 5.225

9.  A mouse model of human oral-esophageal cancer.

Authors:  Oliver G Opitz; Hideki Harada; Yasir Suliman; Ben Rhoades; Norman E Sharpless; Ralph Kent; Levy Kopelovich; Hiroshi Nakagawa; Anil K Rustgi
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

10.  Dicer1 functions as a haploinsufficient tumor suppressor.

Authors:  Madhu S Kumar; Ryan E Pester; Cindy Y Chen; Keara Lane; Christine Chin; Jun Lu; David G Kirsch; Todd R Golub; Tyler Jacks
Journal:  Genes Dev       Date:  2009-11-10       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.